Provided by Tiger Fintech (Singapore) Pte. Ltd.

Seres Therapeutics

13.99
-0.2700-1.89%
Post-market: 13.990.00000.00%16:10 EDT
Volume:47.06K
Turnover:651.98K
Market Cap:122.17M
PE:1.56
High:14.10
Open:14.00
Low:13.38
Close:14.26
Loading ...

Seres Therapeutics Announces CEO Resignation and New Appointments

TIPRANKS
·
23 Jul

Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025

GlobeNewswire
·
22 Jul

Seres Therapeutics Inc - Eric Shaff Steps Down as CEO, Remains Director

THOMSON REUTERS
·
22 Jul

Seres Therapeutics Inc - Appoints Thomas Desrosier and Marella Thorell as Co-Ceos

THOMSON REUTERS
·
22 Jul

Seres Therapeutics Announces Leadership Transition

THOMSON REUTERS
·
22 Jul

Seres Therapeutics Announces Leadership Transition

GlobeNewswire
·
22 Jul

individual investors who own 52% along with institutions invested in Seres Therapeutics, Inc. (NASDAQ:MCRB) saw increase in their holdings value last week

Simply Wall St.
·
20 Jul

Why China's Auto, Tech Giants Threaten Tesla’s Self-Driving Future

Reuters
·
10 Jun

Matthew R. Henn, Officer, Reports Disposal of Common Shares of Seres Therapeutics Inc

Reuters
·
20 May

Seres Therapeutics Shares Fall After Downgrade From Chardan

MT Newswires Live
·
09 May

Chardan Downgrades Seres Therapeutics to Neutral From Buy, Adjusts Price Target to $6 From $25

MT Newswires Live
·
08 May

Seres Therapeutics Cut to Neutral From Buy by Chardan Capital

Dow Jones
·
08 May

Seres Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
07 May

BRIEF-Seres Therapeutics Inc Qtrly EPS $3.76

Reuters
·
07 May

Seres Therapeutics Inc Q1 Shr View $-0.54 -- Lseg Ibes Data

THOMSON REUTERS
·
07 May

Seres Therapeutics Q1 EPS $3.75 Beats $0.12 Estimate

Benzinga
·
07 May

Seres Therapeutics Inc expected to post a loss of 54 cents a share - Earnings Preview

Reuters
·
05 May

Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases

GlobeNewswire
·
29 Apr

Seres Therapeutics trading resumes

TIPRANKS
·
23 Apr

Down -48.7% in 4 Weeks, Here's Why Seres Therapeutics (MCRB) Looks Ripe for a Turnaround

Zacks
·
17 Apr